The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than 50% of the total 162 participating generic name drugs passing the expert review. This approval rate is a decrease compared to 74.2% in 2022 and 63.8% in 2023. The successful drugs included 117 varieties from outside the NRDL and 45 within it.
A total of 445 drugs passed the formality review in this negotiation round, with several innovative drugs being involved in the negotiation for the first time. Notable among them were Akeso Biopharma’s (HKG: 9926) PD-1/CTLA-4 targeted bispecific antibody (BsAb) cadonilimab and PD-1/VEGF-targeted BsAb ivonescimab, Dizal Pharmaceutical Co., Ltd’s (SHA: 688192) EGFR inhibitor sunvozertinib and JAK1 inhibitor golidocitinib, Jingxin Pharmaceutical Co., Ltd’s (SHE: 002020) GABAA regulator Didaxini, and Innovent Biologics Inc.’s (HKG: 1801) tafolecimab, an anti-PCSK-9 monoclonal antibody (mAb).
Multinational pharmaceutical companies also had significant drugs in the spotlight, including AstraZeneca /Daiichi Sankyo’s TROP2-targeted antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-Dxd), Novartis’ siRNA therapy Leqvio (inclisiran), BMS’ TYK2 inhibitor Sotyktu (deucravacitinib), and Roche’s ophthalmology BsAb Vabysmo (faricimab).- Flcube.com
